F-choline PET/MRI on initial staging of prostate cancer. Impact on therapy approach.

Aim: Evaluate the therapy impact of initial staging in patients diagnosed with prostate cancer by F-choline PET/MRI hybrid technique.

Material: A prospective study which included 31 patients diagnosed with prostate cancer; Gleason > 7; mean PSA 13.6 ng/mL (range 6.

Standardization of acquisition protocols using PET/CT with F-Choline in prostate cancer.

Aim: To standardize acquisition protocols for F-Choline PET/CT to prevent from urine interference, to determine the best time point for the whole-body study, and to assess whether "dual point" acquisition allows for differentiating malignant vs. benign lesions.

Methods: One hundred consecutive patients with prostate cancer were prospectively studied.

Value of F-Choline PET/MRI hybrid technique on the therapeutic approach for patients with prostate cancer treated with prostatectomy and rising prostate specific antigen levels below 1 ng/ml.

Objective: To assess the detection rate of F-Choline PET/MRI and subsequent changes in therapy approach for patients with prostate cancer treated by prostatectomy and with rising levels of PSA <1 ng/ml.

Methods: Prospective study with our first 36 patients with prostatectomy for prostate cancer and rising levels of PSA, who were referred for an F-Choline PET/MRI study. A dual-phase study was acquired after intravenous administration of 185±10% MBq of F-Choline: 1) early imaging (immediately after tracer administration) of prostate area (emission PET/Multiparametric MRI).